Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders-Reference-Cited by-同舟云学术

Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders

Published:2020-02-25 Issue:6 Volume:63 Page:2854-2876
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Dou Xiaozheng¹²,Nath Dinesh¹²,Shin Henry³,Nurmemmedov Elmar⁴,Bourne Philip C.²,Ma Jian-Xing³,Duerfeldt Adam S.¹²^ORCID

Affiliation:

1. Institute for Natural Products Applications and Research Technologies, University of Oklahoma, 101 Stephenson Parkway, Stephenson Life Sciences Research Center, Norman, Oklahoma 73019, United States

2. Department of Chemistry & Biochemistry, University of Oklahoma, 101 Stephenson Parkway, Stephenson Life Sciences Research Center, Norman, Oklahoma 73019, United States

3. Department of Physiology, University of Oklahoma Health Sciences Center, 941 Stanton L. Young Boulevard, Oklahoma City, Oklahoma 73104, United States

4. John Wayne Cancer Institute & Pacific Neuroscience Institute at Providence Saint John’s Health Center, 2200 Santa Monica Boulevard, Santa Monica, California 90404, United States

Funder

National Eye Institute

University of Oklahoma

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01189

Reference31 articles.

1. Diabetic retinopathy - ocular complications of diabetes mellitus